Evista (raloxifene hydrochloride)
Company: Eli LillyApproval Status: Approved September 1999
Treatment for: For the treatment of osteoporosis in postmenopausal women.
Areas: Diabetes / Endocrinology; Musculoskeletal; Pregnancy & Gynecology
Possible similar drugs: Evista; Evista
| General Information | Mechanism of Action |
General Information
Tablet of raloxifene hydrochloride for the treatment of osteoporosis in post-menopausal women.
Mechanism of Action
Tablet, 60 mg.
Evista Drug Information
The Evista drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
